Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 29, 2004

View Archived Issues

New glycogen phosphorylase inhibitors discovered at Yamanouchi

New DPP-IV inhibitors prepared and tested by Sanwa Kagaku scientists

Kissei presents new SGLT-1 inhibitors for diabetes and related disorders

Novel GnRH antagonists in early development at Takeda

Chugai claims new vitamin D analogues and their use in calcium metabolism disorders

Takeda researchers discover new agonists of the bile acid-responsive receptor TGR5

Novel oligoadenylic acid derivatives for use in cancer and viral infections

Novel steryl sulfatase inhibitors discovered at Kyowa Hakko

Bicifadine enters acute pain phase III trial

Third indication studied for SGN-30 in new phase II trial

New phase I study evaluates RG-1068 for obsessive-compulsive disorder

Acambis receives fast track status for MVA program

Glenmark and Forest collaborate on GRC-3886

Phase IIa study of BXL-628 for BPH meets primary endpoint

Takeda submits NDA for ramelteon for insomnia

Dosing commences in study of controlled-release oral RSD-1235

Enrollment open in phase I study of AQ4N

Non-approvable letter for oral tazarotene

FDA Advisory Committee to review Marqibo in December

Adalimumab promotes clinical remission in moderate to severe Crohn's disease

FibroGen licenses FG-2216 to Yamanouchi for Japan

Update on the efficacy of cilansetron in diarrhea-predominant IBS

Y-40138 protective in hepatitis models

ECO-4601 shown to cross blood-brain barrier

Canadian approval for phase I trial of Occlusin

Reduced GI tract mucosal injury seen with AZD-3582

DA-6034 safe but poorly absorbed in healthy subjects

BPC-157 lessens effects of alcohol intoxication and withdrawal

PTK-787/ZK-222584 enhances antitumor activity of NVP-LAQ-824

COX inhibition, antiinflammatory action of imrecoxib described

Inhibition of Hsp90 in the treatment of SCLC

ZD-4054 specifically inhibits ETA receptor-mediated antiapoptotic events

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...